The Inhibition of NLRP3 Inflammasome and IL-6 Production by Hibiscus noldeae Baker f. Derived Constituents Provides a Link to Its Anti-Inflammatory Therapeutic Potentials
Tomani, Jean Claude Didelot; Kagisha, Vedaste; Tchinda, Alembert Tiabouet al.
[en] The activation of NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome and/or its components is associated with the physio-pathogenesis of many respiratory diseases including asthma, COPD (chronic obstructive pulmonary disease), SARS Cov-2 (severe acute respiratory syndrome coronavirus 2), and in several autoimmune diseases. Hibiscus noldeae Baker f. has been widely reported to be traditionally used in the treatment of different ailments, some of which are of inflammatory background such as asthma, wounds, headache, etc. However, the claims have not been supported by evidence at the molecular and functional levels. Here, we report on the bio-guided fractionation of H. noldeae and assessment of the inhibitory properties of some fractions and purified compounds on NLRP3 inflammasome and Interleukin 6 (IL-6). The activation of the NLRP3 inflammasome was determined by detecting the activity of caspase-1 and the production of Interleukin 1β (IL-1β) in Lipopolysaccharide (LPS) and ATP-stimulated Tamm-Horsfall Protein 1 (THP-1) macrophages, while the production of IL-6 was studied in LPS-stimulated RAW264.7 mouse macrophages. It was observed that hexane and ethyl acetate fractions of the crude extract of the aerial parts of H. noldeae, as well as caffeic acid, isoquercetin, and ER2.4 and ER2.7 fractions revealed significant inhibitory effects on Caspase-1 activities, and on IL-1β and IL-6 production. The ER2.4 and ER2.7 fractions downregulated the production of IL-1β and IL-6, in a similar range as the caspase-1 inhibitor AC-YVAD-CHO and the drug Dexamethasone, both used as controls, respectively. Overall, our work does provide the very first scientific based evidence for Hibiscus noldeae anti-inflammatory effects and widespread use by traditional healers in Rwanda for a variety of ailments.
Jansen, Olivia ; Université de Liège - ULiège > Département de pharmacie > Pharmacognosie
Ledoux, Allison ; Université de Liège - ULiège > Département de pharmacie > Pharmacognosie
Vanhamme, Luc
Frederich, Michel ; Université de Liège - ULiège > Département de pharmacie > Pharmacognosie
Muganga, Raymond
Souopgui, Jacob
Language :
English
Title :
The Inhibition of NLRP3 Inflammasome and IL-6 Production by Hibiscus noldeae Baker f. Derived Constituents Provides a Link to Its Anti-Inflammatory Therapeutic Potentials
Publication date :
2020
Journal title :
Molecules
eISSN :
1420-3049
Publisher :
Multidisciplinary Digital Publishing Institute (MDPI), Switzerland
Marciniuk, D.; Ferkol, T.; Nana, A.; de Oca, M.M.; Rabe, K.; Billo, N.; Zar, H. Respiratory Diseases in the World. Realities of Today—Opportunities for Tomorrow; European Respiratory Society: Sheffield, UK, 2013; Volume 53.
The Global Asthma Network. The Global Asthma Report 2018; The Global Asthma Network: Auckland, New Zealand, 2018.
Besnard, G.; Togbe, D.; Couillin, I.; Tan, Z.; Zheng, S.G.; Erard, F.; Le Bert, M.; Quesniaux, V.; Ryffel, B.
Inflammasome-IL-1-Th17 response in allergic lung inflammation. J. Mol. Cell Biol. 2012, 4, 3–10. [CrossRef] 4. Kiboneka, A.; Kibuule, D. The Immunology of Asthma and Allergic Rhinitis. Rhinosinusitis 2019. [CrossRef] 5. Ye, H.; Wang, Y.; Yan, J.; Jenson, A.B. Characterization of the anti-inflammation mechanism for the AO herbal extract. Exp. Mol. Pathol. 2016, 101, 341–345. [CrossRef]
Wanderer, A.A. Interleukin-1β targeted therapy in severe persistent asthma (SPA) and chronic obstructive pulmonary disease (COPD): Proposed similarities between biphasic pathobiology of SPA/COPD and ischemia-reperfusion injury. Isr. Med. Assoc. J. 2008, 10, 837–842.
Li, X.; Geng, M.; Peng, Y.; Meng, L.; Lu, S. Molecular Immune Pathogenesis and Diagnosis of COVID-19. J. Pharm. Anal. 2020, 10, 102–108. [CrossRef]
Rothan, H.A.; Byrareddy, S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun. 2020, 109, 102433. [CrossRef]
Sun, X.; Wang, T.; Cai, D.; Hu, Z.; Chen, J.; Liao, H.; Zhi, L.; Wei, H.; Zhang, Z.; Qiu, Y.; et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020, 53, 38–42. [CrossRef]
Pinkerton, J.W.; Kim, R.Y.; Robertson, A.A.B.; Hirota, J.A.; Wood, L.G.; Knight, D.A.; Cooper, M.A.; O’Neill, L.A.J.; Horvat, J.C.; Hansbro, P.M. Inflammasomes in the lung. Mol. Immunol. 2017, 86, 44–55. [CrossRef]
Madouri, F.; Guillou, N.; Fauconnier, L.; Marchiol, T.; Rouxel, N.; Chenuet, P.; Ledru, A.; Apetoh, L.; Ghiringhelli, F.; Chamaillard, M.; et al. Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation. J. Mol. Cell Biol. 2015, 7, 351–365. [CrossRef]
Lin, X.; Liu, M. Pharmacological Use of NLRP3 Inflammasome Inhibitors: Novel Intervention Strategies in Diabetes-Associated Vascular Complications. J. Adv. Ther. Med. Innov. Sci. 2017, 2, 35–36.
Kozloski, G.A. Inflammasome. Mater. Methods 2020, 10, 2869. [CrossRef]
Sollberger, G.; Strittmatter, G.E.; Garstkiewicz, M.; Sand, J.; Beer, H.D. Caspase-1: The inflammasome and beyond. Innate Immun. 2014, 20, 115–125. [CrossRef] [PubMed]
Theofani, E.; Semitekolou, M.; Morianos, I.; Samitas, K.; Xanthou, G. Targeting NLRP3 Inflammasome Activation in Severe Asthma. J. Clin. Med. 2019, 8, 1615. [CrossRef] [PubMed]
Borthwick, L.A. The IL-1 cytokine family and its role in inflammation and fibrosis in the lung. Semin. Immunopathol. 2016, 38, 517–534. [CrossRef] [PubMed]
Nile, S.H.; Nile, A.; Qiu, J.; Li, L.; Jia, X.; Kai, G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020, 53, 66–70. [CrossRef]
Horby, P.; Lim, W.S.; Emberson, J.R.; Mafham, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; Elmahi, E.; et al. Dexamethasone in Hospitalized Patients with Covid-19—Preliminary Report. N. Engl. J. Med. 2020. [CrossRef]
Dhimolea, E. Canakinumab. mAbs 2010, 2, 3–13. [CrossRef]
Tomani, D.C.J.; Olive Lea, G.T.; Nshutiyayesu, S.; Mukazayire, M.J.; Stevigny, C.; Frederich, M.; Muganga, R.; Souopgui, J. An ethnobotanical survey and inhibitory e ff ects on NLRP3 in fl ammasomes/Caspase-1 of herbal recipes’ extracts traditionally used in Rwanda for asthma treatment. Ethnopharmacology 2018, 227, 29–40. [CrossRef]
Vasudeva, N.; Sharma, S.K. Biologically Active Compounds from the Genus Hibiscus. Pharm. Biol. 2008, 46, 145–153. [CrossRef]
Kapepula, P.M.; Ngombe, N.K.; Tshibangu, P.T.; Tsumbu, C.; Franck, T.; Mouithys-Mickalad, A.; Mumba, D.; Katumbay, D.T.; Serteyn, D.; Tits, M.; et al. Comparison of metabolic profiles and bioactivities of the leaves of three edible Congolese Hibiscus species. Nat. Prod. Res. 2017, 31, 2885–2892. [CrossRef]
Sogo, T.; Terahara, T.; Hisanaga, N.; Kumamoto, A.; Yamashiro, T.; Wu, T.; Sakao, S.K.; Hou, D.-X. Anti-inflammatory activity and molecular mechanism of delphinidin 3-sambubioside, a Hibiscus anthocyanin. Int. Union Biochem. Mol. Biol. 2015, 41, 58–65.
Dubois, H.; Sorgeloos, F.; Sarvestani, S.T.; Martens, L.; Saeys, Y.; Mackenzie, J.M.; Lamkanfi, M.; van Loo, G.; Goodfellow, I.; Wullaert, A. Nlrp3 inflammasome activation and Gasdermin D-driven pyroptosis are immunopathogenic upon gastrointestinal norovirus infection. PLoS Pathog. 2019, 15, e1007709. [CrossRef]
Kelley, N.; Jeltema, D.; Duan, Y.; He, Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int. J. Mol. Sci. 2019, 20, 3328. [CrossRef]
Chifundera, K. Contribution to the inventory of medicinal plants from the Bushi area, South Kivu Province, Democratic Republic of Congo. Fitoterapia 2001, 72, 351–368. [CrossRef]
Telefo, P.B.; Lienou, L.L.; Yemele, M.D.; Lemfack, M.C.; Mouokeu, C.; Goka, C.S.; Tagne, S.R.; Moundipa, F.P. Ethnopharmacological survey of plants used for the treatment of female infertility in Baham, Cameroon. J. Ethnopharmacol. 2011, 136, 178–187. [CrossRef]
Yemele, M.D.; Telefo, P.B.; Lienou, L.L.; Tagne, S.R.; Fodouop, C.S.P.; Goka, C.S.; Lemfack, M.C.; Moundipa, F.P. Ethnobotanical survey of medicinal plants used for pregnant womens health conditions in Menoua division-West Cameroon. J. Ethnopharmacol. 2015, 160, 14–31. [CrossRef]
Gurib-Fakim, A. Medicinal plants: Traditions of yesterday and drugs of tomorrow. Mol. Asp. Med. 2006, 27, 1–93. [CrossRef]
Schramm, D.; German, J. Potential effects of flavonoids on the etiology of vascular disease. J. Nutr. Biochem. 1998, 9, 560–566. [CrossRef]
Formica, J.; Regelson, W. Review of the biology of quercetin and related bioflavonoids. Food Chem. Toxicol. 1995, 33, 1061–1080. [CrossRef]
Peltzer, N.; Walczak, H. Cell Death and Inflammation—A Vital but Dangerous Liaison. Trends Immunol. 2019, 40, 387–402. [CrossRef]
Akbar, S. Handbook of 200 Medicinal Plants: A Comprehensive Review of Their Traditional Medical Uses and Scientific Justifications; Springer International Publishing: New York, NY, USA, 2020.
Wang, H.; Guo, X.; Liu, J.; Li, T.; Fu, X.; Liu, R.H. Comparative suppression of NLRP3 inflammasome activation with LPS-induced inflammation by blueberry extracts (Vaccinium spp.). R. Soc. Chem. Adv. 2017, 7, 28931–28939. [CrossRef]
LEE, S.W.; Tsou, A.-P.; Chan, H.; Thomas, J.; Petrie, K.; Eugui, E.M.; Allison, A.C. Glucocorticoids selectively inhibit the transcription of the interleukin 1,f gene and decrease the stability of interleukin 1,8 mRNA. Proc. Natl. Acad. Sci. USA 1988, 85, 1204–1208. [CrossRef]
Lee, H.E.; Yang, G.; Kim, N.D.; Jeong, S.; Jung, Y.; Choi, J.Y.; Park, H.H.; Lee, J.Y. Targeting ASC in NLRP3 inflammasome by caffeic acid phenethyl ester: A novel strategy to treat acute gout. Sci. Rep. 2016, 6, 38622. [CrossRef]
Rogerio, A.; Pereira, A. Quercetin as Drug to Treat Asthma—What is Missing? Austin J. Asthma 2017, 1, 1002.
Reddy, N.; Navanesan, S.; Sinniah, S.; Wahab, N.; Sim, K. Phenolic content, antioxidant effect and cytotoxic activity of Leea indica leaves. BMC Complement. Altern. Med. 2012, 12, 128. [CrossRef]
da Cunha, F.; Duma, D.; Assreuy, J.; Buzzi, F.; Niero, R.; Campos, M.; Et, A. Caffeic acid derivatives: In vitro and in vivo anti-inflammatory properties. Free Radic. Res. 2004, 38, 1241–1253. [CrossRef]
McGeough, M.D.; Pena, C.A.; Mueller, J.L.; Pociask, D.A.; Broderick, L.; Hoffman, H.M.; Brydges, S.D. Cutting Edge: IL-6 Is a Marker of Inflammation with No Direct Role in Inflammasome-Mediated Mouse Models. J. Immunol. 2012, 189, 2707–2711. [CrossRef]
Zhao, B.; Yang, B.; Men, D.; Li, F.; Xiong, J.; Ding, J.; Huang, Q.; Chen, X.; Liu, Y.; Feng, Y.; et al. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019. Clin. Infect. Dis. 2020. [CrossRef]
Derek, K.C.; Al-Garawi, A.; Llop-Guevara, A.; Pillai, R.A.; Radford, K.; Shen, P.; Walker, T.D.; Goncharova, S.; Calhoun, W.J.; Nair, P.; et al. Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma. Allergy Asthma Clin. Immunol. 2015, 2015, 11–14.
